Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Mauna Kea Technologies
  6. News
  7. Summary
    MKEA   FR0010609263

MAUNA KEA TECHNOLOGIES

(MKEA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Mauna Kea Technologies and Tasly Pharmaceutical Announces the Incorporation of Joint Venture in China

11/07/2022 | 11:45am EST

Mauna Kea Technologies and Tasly Pharmaceutical Group announced the achievement of anew key milestone in their strategic partnership. Tasly Mauna Kea Medical Engineering Technology Co. Ltd., based in the Zheijang province of China, is now legally incorporated with registered capital of RMB 250 million (EUR 35 million).

Tasly Mauna Kea Medical Engineering Technology Co. Ltd. will serve as the exclusive commercial platform for expanding the reach of Cellvizio into the Chinese domestic market and will launch a dedicated platform for neurosurgical applications worldwide.


© S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
MAUNA KEA TECHNOLOGIES -4.17% 0.69 Real-time Quote.73.49%
TASLY PHARMACEUTICAL GROUP CO., LTD 0.86% 11.7 End-of-day quote.8.74%
All news about MAUNA KEA TECHNOLOGIES
01/26Mauna Kea Technologies SA Reports Sales Results for the Fourth Quarter and Full Year of..
CI
01/13Mauna Kea Technologies Announces the Publication of Results of the First in Human Clini..
AQ
01/12Mauna Kea Technologies SA Announces the Publication of Results of the First in Human Cl..
CI
2022Mauna Kea Technologies reports its Financial Results for the First Half of 2022
AQ
2022Mauna Kea Technologies SA Reports Earnings Results for the Half Year Ended June 30, 202..
CI
2022Mauna Kea Technologies and Tasly Pharmaceutical Announces the Incorporation of Joint Ve..
CI
2022Mauna Kea Technologies Announces Success of Clinical Trial on Prediction of Remission i..
AQ
2022Mauna Kea Technologies SA Announces Success of Clinical Trial on Prediction of Remissio..
CI
2022Mauna Kea Technologies SA Reports Sales Results for the Third Quarter and Nine Months o..
CI
2022Mauna Kea Technologies : Announces 2022 Nine Month Sales Results
PU
More news
Financials
Sales 2022 10,4 M 11,4 M 11,4 M
Net income 2022 -7,93 M -8,67 M -8,67 M
Net Debt 2022 25,9 M 28,3 M 28,3 M
P/E ratio 2022 -3,62x
Yield 2022 -
Capitalization 30,7 M 33,6 M 33,6 M
EV / Sales 2022 5,43x
EV / Sales 2023 5,44x
Nbr of Employees 71
Free-Float 74,4%
Chart MAUNA KEA TECHNOLOGIES
Duration : Period :
Mauna Kea Technologies Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MAUNA KEA TECHNOLOGIES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,69 €
Average target price 1,93 €
Spread / Average Target 180%
EPS Revisions
Managers and Directors
Sacha Loiseau Chairman & Chief Executive Officer
Shui Gautheron Chief Financial Officer
François Lacombe Chief Scientific Officer
Aline Criton Chief Clinical & Regulatory Affairs Officer
Frédéric Banégas Chief Technology Officer
Sector and Competitors